文献类型：期刊文献

英文题名：Gut-Liver Axis: Modulating the Gut Microbiota and Its Metabolic Products as a Potential Therapeutic Strategy for the Treatment of Hepatic Ischemia-Reperfusion Injury

作者：Wang, Jiahao[1,2];Yun, Yali[1,2];Dong, Xunan[1,2];Wang, Xulong[3];Ma, Haizhong[2,4,5];Fang, Qi[1,2];Xia, Juan[1,2];Tao, Pengxian[4,5,6];Zhang, Dongzhi[1,2,4,5]

第一作者：王谨慧;Wang, Jiahao

通信作者：Zhang, DZ[1];Zhang, DZ[2];Tao, PX[3];Zhang, DZ[3];Tao, PX[4];Zhang, DZ[4];Tao, PX[5]

机构：[1]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Prov Hosp, Emergency Dept, Lanzhou 730000, Gansu, Peoples R China;[3]Zhangye Second Peoples Hosp, Trauma Ctr, Zhangye 734000, Gansu, Peoples R China;[4]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou 730000, Gansu, Peoples R China;[5]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Gansu, Peoples R China;[6]Gansu Prov Hosp, Cadre Ward Gen Surg Dept, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Emergency Dept, Lanzhou 730000, Gansu, Peoples R China;[3]corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou 730000, Gansu, Peoples R China;[4]corresponding author), Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Gansu, Peoples R China;[5]corresponding author), Gansu Prov Hosp, Cadre Ward Gen Surg Dept, Lanzhou 730000, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2024

卷号：36

期号：189

起止页码：1955

外文期刊名：DISCOVERY MEDICINE

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001340228200003)】；

基金：This work was supported: The 2021 Natural Science Foundation of Gansu Province (21JR1RA031) ; Clinical Research Project (23GSSYD-22) ; The 2022 Natural Science Foundation of Gansu Province (2022-0405-JCC-0319, 20JR5RA145) ; Key project of science and technology innovation platform fund of Gansu Provincial People's Hospital (21gssya-4, 16gssy2-5) ; Postdoctoral Fund of Gansu Provincial People's Hospital (NHCDP2022010, NHCDP2022025) .

语种：英文

外文关键词：liver transplantation; liver injury; ischemia-reperfusion injury; gut microbiota; metabolic derivatives

摘要：Hepatic ischemia-reperfusion injury (HIRI) is a major complication reported in various clinical scenarios such as liver transplantation (LTx), hepatectomy, and acute hepatic insult. This condition affects the restoration of hepatic functionalities post-LTx. Contemporary scientific inquiries have highlighted the involvement of intestinal microbiota and their metabolic by-products in the initiation and progression of HIRI. Perturbations in the gut microbiome, instigated by external stressors such as inflammatory processes, ischemic conditions, and reperfusion events, affect the biosynthesis of metabolites such as short-chain fatty acids (SCFAs), bile acids (BAs), and lipopolysaccharides (LPS). SCFAs can exert anti-inflammatory effects, modulate cellular apoptosis, and attenuate oxidative stress, thereby ameliorating hepatic injury. Other studies have shown that the intestinal microbiota confers hepatoprotective effects by modulating the host's immune response and synthesis of cytokines, controlling inflammation, and enhancing liver protection. This review comprehensively describes the mechanisms underlying the association of gut microbiota and its metabolites with hepatic disease and ischemia-reperfusion injury. The findings from recent studies investigating the gut-liver axis are reviewed to identify therapeutic avenues for the prevention and treatment of liver dysfunction and ischemia-reperfusion injury. In-so-doing, novel pathways and perspectives can be exploited to develop therapies for the control of inflammatory hepatic ischemia-reperfusion injury, particularly following liver transplantation or surgical intervention.